Overview
On 26 March 2014, orphan designation (EU/3/14/1252) was granted by the European Commission to Raptor Pharmaceuticals Europe B.V., The Netherlands, for cysteamine bitartrate for the treatment of pancreatic cancer.
This medicine is now known as mercaptamine.
In February 2017, Raptor Pharmaceuticals Europe B.V changed name to Horizon Pharma Europe B.V.
In November 2017, Horizon Phama Europe B.V. changed name to Chiesi Orphan B.V.
The sponsorship was transferred to Chiesi Farmaceutici S.p.A., Italy, in May 2018.
Key facts
Active substance |
Cysteamine bitartrate (gastroresistant) (mercaptamine)
|
Intended use |
Treatment of pancreatic cancer
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/14/1252
|
Date of designation |
26/03/2014
|
Sponsor |
Chiesi Farmaceutici S.p.A. |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: